Pinebridge Investments L.P. Raises Position in Haemonetics Co. (NYSE:HAE)

Pinebridge Investments L.P. grew its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,483 shares of the medical instruments supplier's stock after buying an additional 6,727 shares during the quarter. Pinebridge Investments L.P.'s holdings in Haemonetics were worth $1,755,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics in the fourth quarter worth $25,000. Covestor Ltd increased its holdings in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after buying an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new position in Haemonetics in the 4th quarter worth about $62,000. Parkside Financial Bank & Trust lifted its stake in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 240 shares during the period. Finally, AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after acquiring an additional 1,826 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Trading Up 1.0 %

Shares of Haemonetics stock opened at $62.53 on Monday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The company has a fifty day moving average of $62.83 and a 200 day moving average of $72.11. The company has a market capitalization of $3.14 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, sell-side analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HAE. Needham & Company LLC dropped their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Raymond James reiterated a "strong-buy" rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. JMP Securities dropped their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. Finally, Barrington Research dropped their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.